Biotechnology stocks are crashing, but not all biotech stocks are created equal. In fact, I think these three biotech stocks have something that every investor can get excited about: sales and profit growth.
There's no telling where shares in Celgene Corporation (NASDAQ:CELG), Gilead Sciences (NASDAQ:GILD), or BIogen (NASDAQ:BIIB) are heading in the next days or weeks, but all three are biotechnology powerhouses with the kind of staying power that makes them worthy of considering for long-term portfolios.
Still not convinced? In the following slideshow, I tell you which one of these companies' long-term forecast has me giddy, which one has a dirt cheap valuation that makes me think it's a bargain, and which has the financial chops to weather any storm.
Todd Campbell owns shares of Celgene and Gilead Sciences. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may have positions in the companies mentioned. The Motley Fool owns and recommends Celgene and Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.